DOBUTREX 12.5 MG
DOBUTAMINE (DOBUTAMINE HYDROCHLORIDE) : 12.5 MG · DIN 00759538 · PHARMACEUTICAL PARTNERS OF CANADA INC
Health Canada status: CANCELLED POST MARKET
What is DOBUTREX?
DOBUTREX 12.5 MG contains DOBUTAMINE (DOBUTAMINE HYDROCHLORIDE) : 12.5 MG. It is listed in the Health Canada Drug Product Database under DIN 00759538, held by PHARMACEUTICAL PARTNERS OF CANADA INC, supplied as SOLUTION for INTRAVENOUS administration. Health Canada currently lists it as cancelled post market, status dated 13-Feb-2008. Nexara Health is a licensed Canadian wholesale distributor (DEL 3-002896-A) and can source this product for hospitals, pharmacies and clinics. Availability and lead time are confirmed per order.
Product details and regulatory record
| DIN | 00759538 |
|---|---|
| Brand name | DOBUTREX |
| Generic / active ingredient | DOBUTAMINE (DOBUTAMINE HYDROCHLORIDE) : 12.5 MG |
| Manufacturer | PHARMACEUTICAL PARTNERS OF CANADA INC |
| Strength | 12.5 MG |
| Dosage form | SOLUTION |
| Route of administration | INTRAVENOUS |
| Schedule | Prescription |
| ATC code | C01CA07 DOBUTAMINE |
| AHFS class | 12:12.08.08 |
| Biosimilar | No |
| Health Canada status | CANCELLED POST MARKET |
| Status date | 13-Feb-2008 |
| Original market date | 1988-12-31 00:00:00 |
What can be used instead?
Other Canadian products sharing ATC code C01CA07 DOBUTAMINE. 2 of 9 DINs in this group are currently marketed — marketed products are listed first, because that is what can actually be bought. These tables describe supply, not clinical equivalence: substitution rests with the prescriber or pharmacist, and interchangeability is determined provincially.
| Product | Strength | Form | Manufacturer | Health Canada status | DIN |
|---|---|---|---|---|---|
| DOBUTAMINE INJECTION USP | 12.5 MG | SOLUTION | HIKMA CANADA LIMITED | MARKETED | DIN 02462729 |
| DOBUTAMINE INJECTION USP | 12.5 MG | LIQUID | SANDOZ CANADA INCORPORATED | MARKETED | DIN 02242010 |
| DOBUTAMINE 12.5MG/ML | 12.5 MG | SOLUTION | IVAX PHARMACEUTICALS INCORPORATED | CANCELLED POST MARKET | DIN 02229451 |
| DOBUTAMINE HYDROCHLORIDE INJECTION-12.5MG/ML | 12.5 MG | LIQUID | NOVOPHARM LIMITED | CANCELLED POST MARKET | DIN 02228335 |
| DOBUTAMINE HYDROCHLORIDE INJECTION-12.5MG/ML | 12.5 MG | LIQUID | SANOFI CANADA, INC. | CANCELLED POST MARKET | DIN 02225891 |
| DOBUTAMINE INJECTION SDZ | 12.5 MG | SOLUTION | SANDOZ CANADA INCORPORATED | DORMANT | DIN 02384671 |
| DOBUTAMINE INJECTION USP | 12.5 MG | SOLUTION | STERIMAX INC | APPROVED | DIN 02443430 |
| DOBUTAMINE INJECTION USP | 250 MG / 20 ML | SOLUTION | PFIZER CANADA ULC | CANCELLED POST MARKET | DIN 02210401 |
Who else supplies DOBUTAMINE worldwide?
Nexara tracks national medicine registries and published price lists across multiple markets. DOBUTAMINE appears in 17 registered pack listings across 6 markets, published on 4 different national price bases. Where a Canadian route is closed, that is where an alternative route of supply starts — subject to the import rules in both countries.
Registered listings are not stock. Ask us to confirm what can actually be sourced for your order.
How can I get it?
Nexara Health supplies this product to licensed Canadian buyers — pharmacies, hospitals, clinics, licensed distributors, and clinical trial sponsors or their CROs. We confirm stock, pack size, expiry and pricing at the time of quotation. If the product is on backorder or in shortage, we identify equivalent alternatives and import options where permitted.
Ordering questions
Who can buy this from Nexara?
Licensed entities only. Nexara holds Health Canada establishment licence DEL 3-002896-A and ships only to a licensed address.
Is there a minimum order?
Yes, set per product line and per pack multiple rather than on the order total, so you are never asked to buy a part-pack. The minimum for this line is confirmed with your quote.
What is the lead time?
Confirmed per order at quotation, and it depends on current stock position and whether the product is in shortage.
Can Nexara supply this for a clinical trial?
Yes — comparator and background-therapy supply, including sourcing from other markets where a Canadian pack will not satisfy the protocol. Clinical trial supply.